TNF antagonists

Details TNF antagonists TNF antagonists

2005-11-21

2010-10-26

Monshipouri, Maryam (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C435S069100, C435S252300, C435S320100, C536S023100

Reexamination Certificate

active

07820622

ABSTRACT:
TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypeptides of the invention. The polypeptides may be used for the preparation of pharmaceutical compositions, and for treatment of a subject having a pathology mediated by TNF, such as treatment of rheumatoid arthritis.

REFERENCES:
patent: WO95/31540 (1995-11-01), None
patent: WO98/56906 (1998-12-01), None
patent: WO 02/48189 (2002-06-01), None
patent: WO2004/039841 (2004-05-01), None
“ExPASy: the proteomics server for in-depth protein knowledge and analysis” Elizsabeth Gasteiger et al 3784-3788 Nucleic Acids Research, 2003, vol. 31, No. 13, DOI:10.1093
ar/gkg563.
Pennica D., et al (1984) Nature 312:724-729.
“Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin” Pennica D., et al Nature vol. 312 20/27, Dec. 1984, pp. 724-729.

Affiliated with

Also associated with

Rating

TNF antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TNF antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4194577